Cowen Reaffirms “Buy” Rating for NGM Biopharmaceuticals (NGM)

Cowen reissued their buy rating on shares of NGM Biopharmaceuticals (NYSE:NGM) in a research note published on Monday, AnalystRatings.com reports. The firm currently has a $25.00 price target on the stock.

A number of other analysts have also recently commented on NGM. Goldman Sachs Group assumed coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a buy rating and a $22.00 price objective for the company. Citigroup assumed coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a buy rating and a $29.00 price objective for the company.

NGM Biopharmaceuticals stock opened at $14.82 on Monday. NGM Biopharmaceuticals has a one year low of $12.00 and a one year high of $18.75.

In other news, Director Suzanne Sawochka Hooper acquired 7,000 shares of NGM Biopharmaceuticals stock in a transaction that occurred on Monday, April 8th. The stock was bought at an average price of $16.00 per share, for a total transaction of $112,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Merck & Co., Inc. acquired 4,121,683 shares of NGM Biopharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average price of $16.00 per share, with a total value of $65,946,928.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,253,606 shares of company stock valued at $67,785,862.

NGM Biopharmaceuticals Company Profile

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

See Also: Fundamental Analysis

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.